JP Morgan Private Wealth Advisors’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$25.6K Hold
18,300
﹤0.01% 1709
2023
Q2
$10.1K Hold
18,300
﹤0.01% 1460
2023
Q1
$12.4K Buy
+18,300
New +$23.3K ﹤0.01% 1923
2022
Q4
Sell
-18,300
Closed -$85K 2003
2022
Q3
$85K Hold
18,300
﹤0.01% 1883
2022
Q2
$93K Hold
18,300
﹤0.01% 1876
2022
Q1
$130K Buy
+18,300
New +$123K ﹤0.01% 1943

Other funds holding STLN

JP Morgan Private Wealth Advisors's STLN Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors held its Starling Oncology Institute, Inc. Common Stock (STLN) position steady in Q3 2023 at 18,300 shares worth $25.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1709.

JP Morgan Private Wealth Advisors first reported a position in STLN in Q1 2022 and has held it in 6 quarters since. The position peaked at $130K in Q1 2022. 36 funds tracked by Wall St. Rank hold STLN as of Q3 2023.

  • JP Morgan Private Wealth Advisors held 18,300 shares of Starling Oncology Institute, Inc. Common Stock worth $25.6K as of Q3 2023.
  • JP Morgan Private Wealth Advisors left its Starling Oncology Institute, Inc. Common Stock share count unchanged in Q3 2023.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1709 holding.
  • JP Morgan Private Wealth Advisors first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2022 and has held it in 6 quarters since.
  • JP Morgan Private Wealth Advisors's Starling Oncology Institute, Inc. Common Stock position peaked at $130K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.